Schering Plough Articles
CELLTECH, SCHERING CORP ANTIBODY DEAL
18 January 1993
NEW YORK STOCK COMMENT
4 January 1993
UK INDUSTRY PROTEST OVER NHS LIST PLANS
4 January 1993
NEW YORK STOCK COMMENT
21 December 1992
SHIONOGI LAUNCH
21 December 1992
CLINTON TEAM IN TALKS WITH INDUSTRY
21 December 1992
WELLCOME'S US "TIDAL WAVE" REVERSING?
21 December 1992
NEW YORK STOCK COMMENT
14 December 1992
ICI AT "BREAKING POINT" WITH DEMERGER
14 December 1992
SCHERING-PLOUGH IN SPANISH R&D DEAL
7 December 1992
US DRUG ANALYSTS VIEW CLINTON WIN
9 November 1992
LEUCOMAX LAUNCH IN UK
9 November 1992
US RESULTS 3RD QTR
2 November 1992
FOCUS ON IVAX PRODUCT PIPELINE
12 October 1992
ANALYST'S ESTIMATES OF US THIRD QTR EARNINGS
12 October 1992
NEW YORK STOCK COMMENT
5 October 1992
NEW YORK STOCK COMMENT
7 September 1992
FURTHER INDICATION FOR INTRON A
3 August 1992
US PRICE MODERATION "VARIES BY COMPANY"
3 August 1992
GOOD GROWTH FOR US COMPANIESCONTINUES FOR US COs
3 August 1992
CANADA TOUGHENS ANTIHISTAMINES STANCE
3 August 1992
US PRICE MODERATION "VARIES BY COMPANY"
3 August 1992
Joseph Connors joins Schering-Plough
6 July 1992
management swap at schering-plough
6 July 1992
SCHERING-PLOUGH IN UK CANCER DRUG DEAL
6 July 1992
STRONG GROWTH AT SCHERING-PLOUGH
29 June 1992
US PHARMA INDEX LAUNCHED
29 June 1992
WORLD PRODUCT NEWS IN BRIEF
15 June 1992
ITALY'S RECORDATI LOOKS FOR EXPANSION
15 June 1992
B-MS WARNING WITH EARNINGS FORECAST CUT
8 June 1992
&US DRUG COS UNDER-PERFORM IN FIRST QTR
8 June 1992
stock commentary: New York
1 June 1992
US DRUG FIRMS' PUERTO RICO TAX CREDITS
25 May 1992
"GREAT STRIDES" FOR SCHERING-PLOUGH
18 May 1992
EUROPEAN MARKET FOR SELF-MEDICATION
18 May 1992
S-P BACKs TOKYO INSTITUTE WITH $2.5m
4 May 1992
COMPANIES DO MORE LICENSING DEALS
4 May 1992
GOOD SALES GROWTH FOR MAJOR US COS IN 1st QTR
27 April 1992
STOCK MARKET COMMENTARY: NEW YORK
13 April 1992
S-P HEALTHCARE PRODUCTS CANADA
13 April 1992
VOLUME GROWTH FOR US DRUGMAKERS
9 March 1992
NORTH AMERICA'S OTC COUGH COLD MARKET
9 March 1992
US OTC DRUGMAKERS A TAKEOVER TARGET
17 February 1992
GOOD 1991 RESULTS FOR MERCK AND FOREST LABS
3 February 1992
ALZHEIMER'S DISEASE: US CONCERN
27 January 1992
1991 A YEAR OF STRONG GROWTH IN THE USA
27 January 1992
STOCK MARKET COMMENTARY: NEW YORK
27 January 1992
CHANGES AT SCHERING-PLOUGH RESEARCH
27 January 1992
STOCK MARKET COMMENTARY: NEW YORK
20 January 1992
FAVORABLE FORECASTS FOR US BIOTECH
13 January 1992
STOCK MARKET COMMENTARY: NEW YORK
13 January 1992
CHANGES AHEAD FOR Rx PHARMA INDUSTRY?
6 January 1992
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
